Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Potassium-transporting ATPase

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1995

6

2011

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Active duodenal ulcer

6

Erosive esophagitis

6

Gastric ulcer

6

Gastroesophageal reflux disease

6

Heartburn

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

6

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Takeda Chemical Industries

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

5

SMS_ID

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR ACID RELATED DISORDERS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Proton pump inhibitors

2

Combinations for eradication of Helicobacter pylori

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LANSOPRAZOLE

0K5C5T2QPG

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

BENZIMIDAZOLE

E24GX49LD8

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

AG-2000 FREE BASE

7EMR32786O

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

LEVOLANSOPRAZOLE

FB55O16184

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

DEXLANSOPRAZOLE SESQUIHYDRATE

HS2S9VK3NH

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

LANSOPRAZOLE SODIUM

GV9NY1U369

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

DEXLANSOPRAZOLE

UYE4T5I70X

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Potassium-transporting ATPase

Potassium-transporting ATPase

Potassium-transporting ATPase

Conditions:

Active duodenal ulcer

Gastroesophageal reflux disease

Erosive esophagitis

Gastroesophageal reflux disease

Active duodenal ulcer

Levolansoprazole is the levorotary (L-enantiomer) form of proton-pump inhibitor (PPI) Lansoprazole. Lansoprazole is a racemic 1:1 mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and Levolansoprazole. Lansoprazole has use...

d to the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Levolansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of Levolansoprazole).

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1